US Stock Market Movement: Twist Bioscience surges on September 24th as Eli Lilly TuneLab and AI-driven drug development attract attention

Twist Bioscience September 24 Surge Interpretation

Keywords: Eli Lilly TuneLab, AI drug development

1. On September 16, the company reached an agreement with Eli Lilly's TuneLab to provide antibody characterization data services. Through a preferred agreement, Twist Bioscience will generate high-quality wet lab data to support TuneLab’s AI/machine learning drug discovery model and AbLab antibody developability prediction model, expanding the application scenarios for antibody discovery services.

2. On September 17, Leerink Partners maintained the company's Buy rating and raised the target price from $110 to $160. The company’s main business includes DNA synthesis, protein solutions, and NGS applications. The institution also mentioned the company's plan to double its annual revenue by fiscal year 2031.

3. The financial results disclosed on August 3 for the quarter ended June 30 showed that the company’s revenue increased by 23% year-on-year to $118.4 million. Among this, DNA synthesis and protein solutions revenue grew by 39%, NGS applications revenue grew by 12%, and gene shipment volume surged by 56% year-on-year to approximately 369,000 strands.

(Disclaimer: This content is generated by AI technology based on publicly available information for summary and reference only, and does not constitute investment advice.)